- Home
- BETR vs TLSA Comparison
BETR vs TLSA Comparison
Compare BETR & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BETR
- TLSA
- Stock Information
- Founded
- BETR 2014
- TLSA 2013
- Country
- BETR United States
- TLSA United Kingdom
- Employees
- BETR N/A
- TLSA N/A
- Industry
- BETR Finance: Consumer Services
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- BETR Finance
- TLSA Health Care
- Exchange
- BETR Nasdaq
- TLSA Nasdaq
- Market Cap
- BETR 203.4M
- TLSA 187.0M
- IPO Year
- BETR N/A
- TLSA 2000
- Fundamental
- Price
- BETR $17.93
- TLSA $2.06
- Analyst Decision
- BETR
- TLSA
- Analyst Count
- BETR 0
- TLSA 0
- Target Price
- BETR N/A
- TLSA N/A
- AVG Volume (30 Days)
- BETR 51.8K
- TLSA 541.9K
- Earning Date
- BETR 08-13-2025
- TLSA 05-06-2025
- Dividend Yield
- BETR N/A
- TLSA N/A
- EPS Growth
- BETR N/A
- TLSA N/A
- EPS
- BETR N/A
- TLSA N/A
- Revenue
- BETR $130,672,000.00
- TLSA N/A
- Revenue This Year
- BETR $55.38
- TLSA N/A
- Revenue Next Year
- BETR $71.18
- TLSA N/A
- P/E Ratio
- BETR N/A
- TLSA N/A
- Revenue Growth
- BETR 69.42
- TLSA N/A
- 52 Week Low
- BETR $7.71
- TLSA $0.63
- 52 Week High
- BETR $21.80
- TLSA $2.60
- Technical
- Relative Strength Index (RSI)
- BETR 65.01
- TLSA 53.26
- Support Level
- BETR $12.74
- TLSA $1.73
- Resistance Level
- BETR $18.47
- TLSA $2.53
- Average True Range (ATR)
- BETR 1.44
- TLSA 0.20
- MACD
- BETR 0.29
- TLSA -0.05
- Stochastic Oscillator
- BETR 90.58
- TLSA 41.25
About BETR Better Home & Finance Holding Company
Better Home & Finance Holding Co is a digital-first homeownership company whose services include mortgage, real estate, title, and homeowners insurance. The company has combined technology innovation and fresh thinking with a deep customer focus with the goal of revolutionizing the homeownership industry.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.